MAPT and Alzheimer disease: Evidence from in vitro studies suggests that CD2AP deficiency is a potential contributor to Aβ and tau pathology, yet it is difficult to determine its function in AD due to the lack of viable Cd2ap knockout mouse models that can reach adulthood.